Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma

American Society of Clinical Oncology (ASCO) - Tập 23 Số 27 - Trang 6540-6548 - 2005
Adrienne H. Brouwers1, Peter F.A. Mulders1, P.H.M. de Mulder1, Wim J.M. van den Broek1, W C Buijs1, C. Mala1, F.B.M. Joosten1, Egbert Oosterwijk1, Otto C. Boerman1, Frans H.M. Corstens1, Wim J.G. Oyen1
1From the Departments of Nuclear Medicine, Urology and Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Wilex AG, München, Germany; and the Department of Radiology, Rijnstate Hospital, Arnhem, The Netherlands

Tóm tắt

Purpose A previous activity dose-escalation study using 131I-labeled chimeric monoclonal antibody cG250 in patients with progressive metastatic renal cell carcinoma (RCC) resulted in occasional therapeutic responses. The present study was designed to determine the safety and therapeutic efficacy of two sequential high-dose treatments with 131I-cG250. Patients and Methods Patients (n = 29) with progressive metastatic RCC received a low dose of 131I-cG250 for assessment of preferential targeting of metastatic lesions, followed by the first radioimmunotherapy (RIT) with 2220 MBq/m2 131I-cG250 (n = 27) 1 week later. If no grade 4 hematologic toxicity was observed, a second low-dose 131I-cG250 (n = 20) was given 3 months later. When blood clearance was not accelerated, a second RIT of 131I-cG250 was administered at an activity-dose of 1110 MBq/m2 (n = 3) or 1665 MBq/m2 (n = 16). Patients were monitored weekly for toxicity, and tumor size was evaluated by computed tomography once every 3 months intervals. Results The maximum-tolerated dose (MTD) of the second RIT was 1,665 MBq/m2 because of dose-limiting hematological toxicity. Based on an intention-to-treat analysis, after two RIT treatments, the disease stabilized in five of 29 patients, whereas it remained progressive in 14 of 29 patients. Two patients received no RIT, and eight of 29 received only one 131I-cG250 RIT because of grade 4 hematologic toxicity, formation of human antichimeric antibodies, or disease progression. Conclusion In patients with progressive end-stage RCC, the MTD of the second treatment was 75% of the MTD of the first RIT. In the majority of patients, two cycles of 131I-cG250 could be safely administered without severe toxicity. No objective responses were observed, but occasionally two RIT doses resulted in stabilization of previously progressive disease.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.50.1.7

10.1097/00001622-199605000-00014

Yagoda A, Petrylak D, Thompson S: Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20:303,1993-321,

10.1056/NEJM199804303381805

Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55,2000-S57, (suppl 1)

10.1200/JCO.1997.15.4.1529

Steffens MG, Boerman OC, de Mulder PH, et al: Phase I radioimmunotherapy of metastatic renal cell carcinoma with I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5:S3268,S3274, 1999 (suppl 10)131

10.1002/ijc.2910380406

Pastorek J, Pastorekova S, Callebaut I, et al: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix- loop-helix DNA binding segment. Oncogene 9:2877,1994-2888,

10.1006/geno.1996.0223

10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q

10.1038/sj.bjc.6690757

10.1053/gast.1997.v112.pm9024293

Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 19:1197,1999-1200,

Steffens MG, Boerman OC, Oyen WJ, et al: Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res 59:1615,1999-1619,

Divgi CR, O'Donoghue JA, Welt S, et al: Phase I clinical trial with fractionated radioimmunotherapy using I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45:1412,2004-1421, 131

10.1002/ijc.2910560424

10.1200/JCO.1999.17.8.2530

10.1002/cncr.10308

10.1002/(SICI)1097-0142(20000115)88:2<333::AID-CNCR13>3.0.CO;2-D

Siegel JA, Yeldell D, Goldenberg DM, et al: Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44:67,2003-76,

Juweid ME, Zhang CH, Blumenthal RD, et al: Prediction of hematologic toxicity after radioimmunotherapy with I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med 40:1609,1999-1616, 131

Stephens S, Emtage S, Vetterlein O, et al: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85:668,1995-674,

10.1007/BF00918141

Gruber R, van Haarlem LJ, Warnaar SO, et al: The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 60:1921,2000-1926,

10.1038/sj.bjc.6601617

10.1016/S1040-8428(01)00107-X

Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693,2002-713,

10.1182/blood.V96.4.1259

Brouwers AH, Buijs WCAM, Oosterwijk E, et al: Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with I or In: An intrapatient comparison. Clin Cancer Res 9:S3953,2003-S3960, (suppl)131 111

Brouwers AH, van Eerd JEM, Frielink C, et al: Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with I, Y, Lu, or Re. J Nucl Med 45:327,2004-337, 131 90 177 186

10.1089/108497803322287619

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 23 Số 27

6540-6548

Thông tin tác giả